lenalidomide has been researched along with Primary Myelofibrosis in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (29.03) | 29.6817 |
| 2010's | 20 (64.52) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Björkholm, M; He, J; Liwing, J; Löfgren, C; Schain, F; Song, C; Vago, E | 1 |
| Al Ali, N; Castillo-Tokumori, F; Komrokji, R; Kuykendall, AT; Lancet, J; Padron, E; Sallman, D; Sweet, K; Talati, C; Yun, S | 1 |
| Antonioli, E; Guglielmelli, P; Loscocco, GG; Mannelli, F; Romano, I; Rotunno, G; Vannucchi, AM; Vergoni, F | 1 |
| Chaudhry, QUN; Iftikhar, R; Khan, MA; Mahmood, SK; Satti, TM; Shahbaz, N | 1 |
| Mahajan, V; Muhrerkar, K; Tiwari, P | 1 |
| Bai, H; Chen, JW; Fan, WJ; Wu, T | 1 |
| Burgstaller, S; Fridrik, M; Gisslinger, H; Hojas, S; Kühr, T; Ludwig, H; Mayrbäurl, B; Pöhnl, R; Pötscher, M; Schlögl, E; Thaler, J; Zauner, D | 1 |
| Chen, L; Gonzalez, MM; Kidd, L; Nguyen, N; Quesada, J | 1 |
| Birgegård, G | 1 |
| Borthakur, G; Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Verstovsek, S; Wang, X; Zhou, L | 1 |
| Aylı, M; Cengiz Seval, G; Özcan, M | 1 |
| Kusec, R; Livun, A; Manshouri, T; Newberry, KJ; Verstovsek, S | 1 |
| Chihara, D; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, H; Maeng, H; Masarova, L; Newberry, KJ; Ravandi, F; Verstovsek, S | 1 |
| Fung, MA; Jagdeo, J; Mayo, K; Petukhova, TA; Tartar, DM; Tuscano, J | 1 |
| Hanson, CA; Ketterling, RP; Knudson, RA; Mesa, RA; Schwager, S; Tefferi, A | 1 |
| Bueso-Ramos, C; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Verstovsek, S | 1 |
| Cripe, LD; Li, CY; Litzow, M; Mesa, RA; Paietta, E; Rowe, JM; Tallman, MS; Tefferi, A; Yao, X | 1 |
| Biemond, BJ | 1 |
| de Witte, T; Holle, N; Mandigers, C; Raymakers, R; Schaap, N | 1 |
| Lacy, MQ; Tefferi, A | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H; Pierce, S; Thomas, D; Verstovsek, S; Zhou, L | 1 |
| Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I | 1 |
| Kolesar, JM; Simondsen, KA | 1 |
| Abruzzo, L; Cortes, J; Kantarjian, H; Pierce, S; Takahashi, K; Verstovsek, S | 1 |
| Bauters, F; Berthon, C; Facon, T; Guieze, R; Kuhnovsky, F; Leleu, X; Micol, JB; Moreau, AS; Terriou, L; Yakoub-Agha, I | 1 |
| Silver, R | 1 |
| Allred, JB; Byrne, C; Cortes, J; Giles, F; Hogan, WJ; Jones, D; Kantarjian, HM; Ketterling, RP; Lasho, TL; Litzow, MR; McClure, RF; Mesa, RA; Tefferi, A; Thomas, D; Verstovsek, S; Zeldis, JB | 1 |
| Davis, MD; Hoverson, AR; Weenig, RH; Wolanskyj, AP | 1 |
| Lancet, JE; List, AF; Moscinski, LC | 1 |
| Hanson, CA; Ketterling, RP; Lasho, TL; Mesa, RA; Pardanani, A; Tefferi, A | 1 |
| Carwile, J; El Rassi, FA; Tam, CS; Verstovsek, S | 1 |
6 review(s) available for lenalidomide and Primary Myelofibrosis
| Article | Year |
|---|---|
[Research and Applications Progress of Lenalidomide for Myelofibrosis--Review].
Topics: Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quality of Life; Thalidomide | 2018 |
Does anything work for anaemia in myelofibrosis?
Topics: Androgens; Anemia; Blood Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Interferons; Lenalidomide; Nitriles; Oxymetholone; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Thalidomide | 2014 |
Thalidomide and lenalidomide in primary myelofibrosis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Hematopoiesis; Humans; Janus Kinase 2; Lenalidomide; Prednisone; Primary Myelofibrosis; Thalidomide | 2010 |
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Thalidomide | 2011 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia | 2011 |
[Thalidomide: mechanisms of action and new insights in hematology].
Topics: Amyloidosis; Angiogenesis Inhibitors; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Forecasting; Hematologic Diseases; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrence; Thalidomide; Time Factors; Waldenstrom Macroglobulinemia | 2005 |
8 trial(s) available for lenalidomide and Primary Myelofibrosis
| Article | Year |
|---|---|
Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway.
Topics: Aged; Busulfan; Danazol; Disease-Free Survival; Female; Follow-Up Studies; Glucocorticoids; Humans; Hydroxyurea; Lenalidomide; Male; Middle Aged; Nitriles; Norway; Pregnancy; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Registries; Survival Rate; Sweden | 2019 |
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Thalidomide; Treatment Outcome | 2015 |
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Remission Induction; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Glucocorticoids; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Neutropenia; Platelet-Derived Growth Factor; Prednisone; Primary Myelofibrosis; Thalidomide; Thrombocytopenia; Transforming Growth Factor beta; Treatment Outcome | 2009 |
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Thalidomide | 2010 |
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Primary Myelofibrosis; Thalidomide; Treatment Outcome | 2011 |
Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Primary Myelofibrosis; Retrospective Studies; Thalidomide | 2013 |
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Topics: Administration, Oral; Adult; Aged; Anemia; Anemia, Myelophthisic; Female; Hemoglobins; Humans; Janus Kinase 2; Lenalidomide; Male; Neovascularization, Pathologic; Neutropenia; Platelet Count; Point Mutation; Primary Myelofibrosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Remission Induction; Sequence Deletion; Splenomegaly; Thalidomide; Thrombocytopenia; Time Factors | 2006 |
17 other study(ies) available for lenalidomide and Primary Myelofibrosis
| Article | Year |
|---|---|
Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
Topics: Aged; Anemia; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Primary Myelofibrosis; Retrospective Studies; Thalidomide | 2020 |
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bone Marrow; Calreticulin; Dexamethasone; Humans; Hydroxyurea; Lenalidomide; Male; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Osteolysis; Primary Myelofibrosis; Remission Induction; Risk Factors; Sequence Deletion; Stomatitis, Aphthous; Thrombocythemia, Essential | 2021 |
Lenalidomide Induced Toxic Epidermal Necrolysis and Del (5q): Co-occurrence of Rarities.
Topics: Anemia, Macrocytic; Calreticulin; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Primary Myelofibrosis; Stevens-Johnson Syndrome | 2018 |
An unusual presentation of primary myelofibrosis.
Topics: Biopsy; Diagnosis, Differential; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Primary Myelofibrosis; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2018 |
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.
Topics: Aged; Aged, 80 and over; Anemia; Austria; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Lenalidomide; Leukopenia; Male; Middle Aged; Primary Myelofibrosis; Thalidomide; Thrombocytopenia; Treatment Outcome | 2013 |
Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma.
Topics: Aged; Blood Cell Count; Bone Marrow; Humans; Immunohistochemistry; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Thalidomide | 2013 |
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
Topics: Aged; Aspergillosis; Blood Transfusion; Danazol; Disease Progression; Drug Resistance; Fatal Outcome; Humans; Hydroxyurea; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid, Acute; Male; Nitriles; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Splenectomy; Splenic Infarction; Thalidomide | 2015 |
Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Clinical Trials, Phase II as Topic; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Thalidomide | 2015 |
Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.
Topics: Aged; Erythema Nodosum; Humans; Immunologic Factors; Janus Kinase 2; Lenalidomide; Male; Panniculitis; Primary Myelofibrosis; Thalidomide | 2016 |
Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 13; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Retrospective Studies; Thalidomide; Trisomy | 2009 |
Treatment considerations for primary myelofibrosis.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Neovascularization, Pathologic; Primary Myelofibrosis; Prognosis; Risk Factors; Thalidomide | 2010 |
Lenalidomide-induced elevated bilirubin.
Topics: Bilirubin; Humans; Lenalidomide; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Thalidomide | 2012 |
Current treatment of myelofibrosis.
Topics: Blood Transfusion; Bone Marrow Transplantation; Clinical Trials as Topic; Dexamethasone; Disease Management; Drug Therapy, Combination; Esophageal and Gastric Varices; Farnesyltranstransferase; Gastrointestinal Hemorrhage; Hematopoietic Cell Growth Factors; Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quinazolines; Spleen; Splenectomy; Thalidomide; Transplantation, Homologous | 2005 |
Neutrophilic dermatosis (Sweet syndrome) of the hands associated with lenalidomide.
Topics: Aged; Diagnosis, Differential; Hand Dermatoses; Humans; Immunologic Factors; Lenalidomide; Male; Primary Myelofibrosis; Sweet Syndrome; Thalidomide | 2006 |
Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
Topics: Acute Disease; Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid; Middle Aged; Primary Myelofibrosis; Remission Induction; Thalidomide | 2007 |
Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Female; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Point Mutation; Primary Myelofibrosis; Remission Induction; Thalidomide | 2007 |
Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis.
Topics: Aged; Humans; Lenalidomide; Male; Penis; Primary Myelofibrosis; Thalidomide; Thrombosis | 2008 |